Validation of the UCLA Scleroderma Clinical Trial Gastrointestinal Tract Instrument Version 2.0 for Juvenile Systemic SclerosisProtocol #: 19-1613 Location: Childrens Hospital Colorado |
The Impact of Pediatric Skin Disorders: The "Big" StudyProtocol #: 18-1380 Location: Childrens Hospital Colorado |
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Krystexxa (pegloticase)(MIRROR Randomized Controlled Trial [RCT])Protocol #: 19-1717 Locations: Barbara Davis Center; University of Colorado Hospital |
Allen CU-UCSD Transition to RA Project: Blood and FluProtocol #: 19-1150 Locations: Barbara Davis Center; University of Colorado Hospital |
Inception Cohort for Juvenile Systemic Sclerosis: A Follow-Up Study Over 3 Years for Children and Young People with Systemic SclerosisProtocol #: 19-0814 Location: Childrens Hospital Colorado |
A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TAK-079 in Combination With Standard Background Therapy in Patients With Moderate to Severe Systemic Lupus ErythematosusProtocol #: 19-0027 Location: Barbara Davis Center |
Controlling and Preventing Asthma Progression and Severity in Kids with OmalizumabRandomized, Double blinded, placebo controlled, multiple-center, parallel arm study with 96 week treatment phase and 96 week observation phase Protocol #: 18-2286 Location: Childrens Hospital Colorado |
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE)Protocol #: 18-2346 Location: University of Colorado Hospital |
Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis (StopRA)Protocol #: 15-1868 Locations: Barbara Davis Center; UCD Barbara Davis Center; University of Colorado Hospital |
A randomized, controlled pilot trial to evaluate the efficacy and safety of subcutaneous Abatacept in treating interstitial lung disease associated with the anti-synthetase syndromeProtocol #: 17-2000 Location: University of Colorado Hospital |
Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease (RAPID)This study is inviting people who have RA into a study to have an HRCT scan and PFT testing done for the study to learn more about lung disease in RA Protocol #: 16-1097 Location: University of Colorado Hospital |
Calibrating free-living physical activity characteristics across functionally-limited populations using machine-learned accelerometer approachesRegular physical activity is known to have positive effects on many health outcomes. In research, physical activity is often measured using activity monitors worn on the hip, wrist or ankle. These instruments determine how much physical activity a person does based on the amount of movement the person does. This is done with equations that use the data collected by the activity monitors. However, these equations are usually developed using measurements on healthy people. People who have movement disorders related to diseases such as Parkinson?s and Multiple Sclerosis, or conditions such as knee replacement, stroke, or arthritis have very different movement patterns than people without these diseases. Thus, the equations used to convert activity monitor data will not work well in people with these diseases or conditions. The purpose of this study is to develop equations to measure physical activity using activity monitors in people with movement limitations. Rather than creating specific equations for each individual disease and condition, we will perform simple tests to measure upper and lower body function, and then group people into different clusters based on these tests. Our preliminary studies show that these equations are more accurate than equations based on specific diseases or conditions. Protocol #: 16-2706 Locations: CTRC-adult; University of Colorado Hospital |
Program for Individuals with an Elevated Risk of Spondyloarthritis (PIERS)The Program for Individuals with an Elevated Risk of Spondyloarthritis (PIERS) is a registry proposed by the affiliate members of the University of Colorado Program to Advance Spondyloarthritis Treatment (U.C.PAST). The purpose of PIERS is to identify individuals at risk for spondyloarthritis and study these individuals in a longitudinal manner in order to better understand the development of spondyloarthritis. Results from this study may provide information that contributes to our understanding of the complex relationships among immune dysregulation, genetic risk, subclinical phenotypes, and established spondyloarthritis phenotypes. Protocol #: 17-0977 Location: University of Colorado Hospital |
Scleroderma Lung Study III (SLS III): Combining the anti-fibrotic effects of pirfenidone (PFD) with mycophenolate (MMF) for treating scleroderma-related interstitial lung diseaseProtocol #: 17-1226 Location: University of Colorado Hospital |
The Colonic Microbiome and Mucosal Immunity in Inflammatory Bowel Disease and Ankylosing SpondylitisThis study uses colonic biopsies to compare immune cell function and gut microbiome between those with IBD, AS, AS/IBD overlap, and healthy controls. To evaluate the relationship between the colonic microbiome and the immune system in AS, IBD, AS+IBD, and healthy controls. Protocol #: 14-1507 Locations: Colorado Research Center; Denver Health Medical Center; University of Colorado Hospital |